The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice

A common therapeutic strategy to combat human cancer is the use of combinations of drugs, each targeting different cellular processes or vulnerabilities. Recent studies suggest that addition of an MCL-1 inhibitor to such anticancer drug treatments could be an attractive therapeutic strategy. Thus, i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Differ
Autori principali: Brinkmann, Kerstin, Grabow, Stephanie, Hyland, Craig D, Teh, Charis E, Alexander, Warren S, Herold, Marco J, Strasser, Andreas
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2017
Soggetti:
Original Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686343/
https://ncbi.nlm.nih.gov/pubmed/28800129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2017.125
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi